Revenue Shift and Market Reaction

Cipla's fourth-quarter results showed a significant year-on-year profit decline, largely driven by the planned exit from the high-margin Revlimid revenue stream. This anticipated shift has focused investor attention on the company's future strategy, especially its progress in the U.S. respiratory market.

Market Looks Past Q4 Profit Drop to US Pipeline Potential

Cipla's shares surged intraday, climbing as much as 4.75% to ₹1,353.8 on Wednesday. This rise occurred despite the announcement of a 55% year-on-year drop in net profit for the fourth quarter to ₹554.6 crore. Revenue fell 3% to ₹6,451.2 crore, and EBITDA contracted 38% to ₹955 crore, with operating margins falling from 22.8% to 14.6%. This market reaction suggests investors are looking past the immediate profit dip, understanding it stems from the loss of generic Revlimid revenues after patent exclusivity ended in January 2026. Cipla's market capitalization of roughly INR 1.15 trillion and a P/E ratio of around 30x indicate investors are anticipating future growth, viewing the current performance as a transitionary phase.

US Respiratory Pipeline Approval Boosts Confidence

Investor optimism is supported by Cipla's U.S. inhalation manufacturing capabilities. The U.S. FDA has approved the first AB-rated generic Ventolin, manufactured entirely at Cipla's U.S. facility. This approval is viewed as a step towards a larger respiratory product launch pipeline expected in fiscal year 2027. The company also expanded its portfolio with drugs like Liraglutide, Nintedanib, and Dapagliflozin for the U.S. market. Furthermore, its key U.S. FDA-inspected facilities received 'VAI' or 'NAI' classifications, easing significant regulatory concerns that had previously affected investor sentiment.

Cipla's "One India" business showed strong performance, growing 15% year-on-year in Q4 across its Branded Prescription, Trade Generics, and Consumer Health segments. Key brands like Foracort surpassed ₹1,000 crore in annual revenue, while the cardiac brand Dytor grew 25% to over ₹650 crore. Overall One India revenue exceeded ₹12,500 crore for the first time, with 60.2% coming from chronic products, highlighting sustained domestic demand and brand strength.

Emerging markets are also contributing significantly, with One Africa growing 21% year-on-year in Q4, led by a 33% surge in South Africa. The EMEU (emerging markets and Europe) business surpassed $400 million in annualized revenues, helping to balance U.S. market pressures. This geographic diversification mirrors wider trends in the Indian pharmaceutical sector, which is benefiting from domestic healthcare growth and a focus on specialized generics in regulated markets, despite ongoing U.S. pricing pressures. Other major Indian drugmakers like Sun Pharma and Dr. Reddy's Laboratories are also showing strong growth, supported by their U.S. portfolios and R&D investments.

Challenges in the US Market and Domestic Reliance

However, significant risks remain despite positive market reactions and approvals. The U.S. generic market faces intense competition and constant price declines, which could affect the profitability of new launches like generic Ventolin, even with domestic manufacturing. While Cipla's U.S. pipeline is diversified, it has yet to match Revlimid's revenue scale, and replicating its high-margin success will be challenging. Competitors like Sun Pharma and Dr. Reddy's have larger U.S. operations and broader product ranges, potentially giving them an edge. Cipla's substantial reliance on the Indian market for growth, though currently a strength, also exposes it to domestic regulatory shifts and intense local competition. Any execution issues in its U.S. respiratory strategy or unexpected regulatory problems could hinder its growth plans.

Financial Strength and Dividend

Cipla ended fiscal year 2026 with a strong net cash position of ₹10,526 crore. The board proposed a final dividend of ₹13 per share for FY26, up from ₹11, signaling confidence in the company's financial health. Analysts view Cipla's strategic shift positively, citing growth potential from its Indian and emerging market businesses, alongside its U.S. pipeline development. Margin recovery in the coming years will depend on the success and pricing of these new product introductions.